A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours

This study has been completed.
Sponsor:
Collaborator:
Aventis Pharmaceuticals
Information provided by (Responsible Party):
Professor David Cunningham, Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00220064
First received: September 19, 2005
Last updated: September 19, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2005
  Estimated Primary Completion Date: No date given